Creo Medical Group PLC Result of General Meeting and Total Voting Rights (8364X)
23 December 2019 - 10:15PM
UK Regulatory
TIDMCREO
RNS Number : 8364X
Creo Medical Group PLC
23 December 2019
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Result of General Meeting
and
Total Voting Rights
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
at the General Meeting held earlier today, all resolutions proposed
were duly passed unanimously by shareholders. Accordingly, the
Company has raised GBP51.9 million in the Fundraising and has
issued and allotted 28,835,173 New Ordinary Shares, conditional
only on Admission becoming effective. Admission of the New Ordinary
Shares is expected at 8.00 a.m. on 24 December 2019.
Following Admission, the Company's issued ordinary share capital
will comprise 150,378,758 Ordinary Shares, of which none are held
in treasury. The above figure of 150,378,758 may be used by
Shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the voting rights of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
A summary of the votes received will be made available on the
Group's website at investors.creomedical.com. Unless otherwise
defined herein, capitalised terms used in this announcement shall
have the same meanings as defined in the circular sent to
shareholders of the Company on 4 December 2019.
Enquiries:
Creo Medical Group plc investors.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Cameron MacRitchie
(NOMAD)
Michael Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7515
909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical Advanced Energy Platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA Advanced Energy
Platform powered by unique full spectrum adaptive technology to
market enabling a suite of medical devices which the Company has
designed, initially for the emerging field of GI therapeutic
endoscopy, an area with high unmet needs. The CROMA Advanced Energy
platform will be developed further for bronchoscopy and laparoscopy
procedures. The Company believes its technology can impact the
landscape of surgery and endoscopy by providing a safer,
less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMMMMZZMFDGLZM
(END) Dow Jones Newswires
December 23, 2019 06:15 ET (11:15 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jul 2023 to Jul 2024